GlassScriptPhysician profile
Timothy Welch
NPI 1275633679
$4,133.59
in general payments reported to CMS, 2019-2025
26 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $85.19 · 2021: $180 · 2022: $311 · 2023: $702 · 2024: $1,198 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $586.33 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $475.32 | 2019-2025 | |
| Cvrx, INC. | $447.48 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $371.48 | 2022-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $340.29 | 2023-2025 | Onpattro |
| Scpharmaceuticals INC. | $255.29 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $252.78 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $209.20 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $172.29 | 2021-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.46 | 2023-2025 | Jardiance |
| Amgen INC. | $159.26 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $106.39 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $74.19 | 2024 | Arcalyst |
| Recor Medical INC | $69.22 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Bayer Healthcare Pharmaceuticals INC. | $66.76 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $66.33 | 2025 | Attruby |
| Novo Nordisk INC | $62.29 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $55.88 | 2022-2024 | Xarelto |
| Esperion Therapeutics, INC. | $43.59 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $42.10 | 2023-2024 | Inpefa |
| Vital Connect, INC | $23.17 | 2023 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $20.53 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.00 | 2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $19.70 | 2019 | |
| Tactile Systems Technology INC | $15.88 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.